leisure time -WSS

leisure time

author：focus 2025-10-02 21:07:19 - browse：6

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — European regulators on Friday reiterated their view that an ALS treatment from Amylyx Pharmaceuticals should not be approved, likely dooming the drug’s chances for now.

A European Medicines Agency committee had initially recommended against approving the drug, known as Albrioza, in June. Friday’s confirmation of that position came after the company appealed the decision. While the European Commission officially decides whether to approve a new medicine, it almost always follows the committee’s guidance. The final decision is expected to be made before the end of the year.

The drug, which won approval last year in the United States and is marketed Relyvrio, is designed to slow the progression of the fatal neurological condition. In its pivotal trial, patients who received the drug over 24 weeks scored about two points better on a 48-point scale of symptoms than those who got a placebo, indicating the drug slowed disease progression.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Readout Newsletter: Amylyx, Aurinia, and IQVIA

WSS

Resistance to opioid

How a Boston hospital is priming medical residents to use GPT

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Why don't Americans have at

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

hotspot

leisure time

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

Websites selling Wegovy, Zepbound ingredients targeted by FDA

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Juul documents reveal insider tactics on political lobbying

Drug repurposing or repositioning? The language matters

Too many hospitalized Covid

Duchenne breakthrough therapy leaves behind pioneering families

Congress must protect the remaining independent doctors

How to save PrEP access — and even expand it

Artificial intelligence use in health care faces greater scrutiny in 2024

knowledge

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Why don't Americans have at

Dementia risk linked to living in disadvantaged areas: Study

How a Boston hospital is priming medical residents to use GPT

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

explore

hotspot

entertainment

entertainment